CTU: A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough

  • Veitch, Elizabeth (Primary Chief Investigator)
  • TAIDI, Gina (Clinical Trial Unit Staff)
  • Martin, Lewis (Clinical Trial Unit Staff)
  • Quinlan, Gabriel (Clinical Trial Unit Staff)
  • Garcia, Michelle (Clinical Trial Unit Staff)
  • Armstrong, Emilia (Clinical Trial Unit Staff)
  • McHugh, Tracey (Clinical Trial Unit Staff)

Project: Research

Project Details

Short title1490-0004
StatusActive
Effective start/end date20/10/24 → 24/07/29